We report on our experience with this novel compound focusing on its pharmacokinetics and pharmacodynamics after induction polychemotherapy. These analyses were performed in the context of a phase II study and were approved by the local ethics committee. Prior to initiation of study medication, all patients gave their written informed consent. Seven days after the end of induction chemotherapy comprising high-dose cytarabine and mitoxantron, 6 mg of pegfilgrastim (Neulasta) was administered subcutaneously in patients showing complete blast clearance in routine bone marrow aspiration. A second injection was scheduled for those patients remaining leukopenic (that is, leukocytes o1 G l -1

SmartRoadSense is a crowdsensing project aimed at monitoring the conditions of the road surface. Using the sensors of a smartphone, SmartRoadSense monitors the vertical accelerations inside a vehicle traveling the road and extracts a roughness index conveying information about the road conditions. The roughness index and the smartphone GPS data are periodically sent to a central server where they are processed, associated with the specific road, and aggregated with data measured by other smartphones. This paper studies how the smartphone vertical accelerations and the roughness index are related to the vehicle speed. It is shown that the dependence can be locally approximated with a gamma (power) law. Extensive experimental results using data extracted from SmartRoadSense database confirm the gamma law relationship between the roughness index and the vehicle speed. The gamma law is then used for improving the SmartRoadSense data aggregation accounting for the effect of vehicle speed.

No abstract

No abstract

Nowadays, there are a lot of new mobile devices that have the potential to assist healthcare professionals when working and help to increase the well-being of the people. These devices comprise the Internet of Medical Things, but it is generally difficult for healthcare institutions to meet compliance of their systems with new medical solutions efficiently. A technology that promises the sharing of data in a trust-less scenario is the Distributed Ledger Technology through its properties of decentralization, immutability, and transparency. The Blockchain and the Internet of Medical Things can be considered as at an early stage, and the implementations successfully applying the technology are not so many. Some aspects covered by these implementations are data sharing, interoperability of systems, security of devices, the opportunity of data monetization and data ownership that will be the focus of this review. This work aims at giving an overview of the current state-of-the-art of the Blockchain-based systems for the Internet of Medical Things, specifically addressing the challenges of reaching user-centricity for these combined systems, and thus highlighting the potential future directions to follow for full ownership of data by users.